ADA 84th Scientific Sessions and Post Conference Forum Recap - New POC A1C Test and Additional Innovative Solutions Unveiled

Stay Informed Ahead of the Next Diabetes Conference in 2025. The ADA’s (American Diabetes Association) 84th Scientific Sessions, held from… June 21–24 in Orlando, Florida, showcased breakthrough research and discussions on the latest advances in diabetes care. This year’s conference focused on themes such as Obesity, Integrated Physiology, Clinical Diabetes, Therapeutics, Epidemiology, and Genetics. Following the sessions, the 18th Annual Diabetes Forum and Reception, hosted by diaTribe and Taking Control of Your Diabetes (T.C.O.Y.D.), provided a destination to discuss further ADA conference highlights with industry leaders. Explore our recap of both events below!

Advancements in Diabetes Care at the 2024 ADA Scientific Sessions and the 18th Annual Diabetes Forum & Reception

POC A1C Testing Advancements Orange Biomed presented cutting-edge research with our poster, “A New HbA1c Test Based on a Cellular Stiffness Measurement of Red Blood Cells.” This groundbreaking study is the first to report the proportionality between HbA1c levels and the cellular stiffness of RBCs, demonstrating significant advancements in diabetes care.

Orange Biomed Rereseting the OBM rapid A1c at ADA 84th Scientific Sessions — **Stiffness Analysis was Conducted on Over 500 RBCs from Each Study Participant**

Our presentation highlighted how the OBM rapid A1c At-Home System, including a reusable, pocket-sized POC A1c meter, provides lab-accurate results from just a single drop of blood. This innovation aims to make diabetes testing more accessible and affordable. Currently undergoing clinical trials in the U.S., the A1C test at home anticipates OTC FDA clearance in 2025. Updates to the 2024 ADA Standards of Care Dr. Nuha El Sayed, Dr. Jason L. Gaglia, Dr. Grazia Aleppo, Dr. Dennis Bruemmer, Dr. Ildiko Lingvay, and Dr. Nicola Napoli presented new changes to team-based care in 2024. Following the panel, Dr. El Sayed returned to the stage to further discuss the economic costs of diabetes in the U.S. Significant updates to the 2024 ADA Standards of Care were shared, focusing on new screening protocols for cardiovascular disease (CVD) and chronic kidney disease (CKD) in people with diabetes. These changes aim to improve early diagnosis and management of these comorbid conditions. AI in Diabetes Care and Drug Development A panel led by Dr. Boris Kovatchev, Dr. Peter G. Jacobs, and Dr. Mudassir M. Rashid focused on artificial intelligence (AI) in health care and the future of diabetes data. The presentation highlighted AI’s impact on diabetes care, such as how AI can revolutionize patient monitoring, personalize treatment plans, predict disease progression, and streamline drug discovery processes. Experts discussed current applications and future possibilities, emphasizing both opportunities and challenges. Obesity Management and Health Equity The symposium on obesity in the U.S. highlighted challenges and strategies for managing diabetes amongst Hispanic/Latino populations. Speakers addressed the evolving landscape of obesity management, emphasizing social determinants of health and health equity. Topics included recent treatment advancements and strategies to ensure equitable access to care, aiming to improve health outcomes. Dr. Erica G. Soltero, Dr. Jeffrey Schwimmer, Dr. Jaime P. Almandoz, and Dr. Carolina Perez-Ferrer were key speakers. Adjunctive Therapies for Type 1 Diabetes An informative session covered adjunctive therapies for type 1 diabetes, including GLP-1 receptor agonists and SGLT2 inhibitors. The session reviewed clinical evidence, benefits, risks, and practical considerations for incorporating these therapies into standard practice to optimize glycemic control. Dr. Ele Ferrannini described SGLT inhibition, while Dr. Michael A. Nauck, MD, covered GLP-1RA in Type 1 diabetes mellitus. Expanding Technology for T1D and T2D The technology session showcased advancements in managing type 1 and type 2 diabetes, including six new hybrid closed-loop (HCL) systems presented by Dr. Jean-Pierre Riveline and several continuous glucose monitors (CGMs). The need for continuous ketone monitoring to prevent diabetic ketoacidosis was also discussed. Automated Insulin Delivery (AID) Systems The presentation on AID systems focused on their use during pregnancy and in specific populations, including those with type 2 diabetes. Benefits, challenges, and insights into tailoring AID use for diverse patient needs were highlighted. Dr. Eleanor Scott and Dr. Christina Seifris led a discussion on pregnancy and reproductive health, detailing how CGM should be used in pregnancy complicated by gestational diabetes. Dr. Ramzi Ajan, Dr. Gregory Norman, Dr. Yogesh Kunda, and Dr. Medha Munshi presented a session on new technology – equity and access. Expanding Uses for SGLT2 Inhibitors and GLP-1 RAs The session on SGLT2 inhibitors and GLP-1 receptor agonists (GLP-1 RAs) explored their expanding therapeutic applications beyond diabetes management. Benefits for heart, kidney, and liver health and potential roles in treating addiction and Parkinson’s disease were discussed. Important safety information for off-target effects on new therapies for diabetes was shared by Dr. Tina Wiespaul, Dr. Ron Goldenberg, Dr. Ann Peters, and Dr. Leanna Billings. The CNS Effects of GLP-1RA were explored beyond diabetes and obesity in a presentation by Dr. Lorenzo Leggio and Dr. Nigel Grieg. Preventing Beta Cell Destruction Strategies to prevent beta cell destruction and preserve or replace islet cells, including immunotherapies, regenerative medicine, and islet cell transplantation, were also covered. The session highlighted recent breakthroughs and prospects in diabetes research. In a joint ADA and IPTA symposium, Dr. David Harlan, Dr. Andrew Posselt, Dr. James Shapiro, and Dr. Ellen Zimmerman led a discussion on clinical replacement therapy today. New Nomenclature and Screening for Liver Diseases A panel introduced new terminology and screening guidelines for metabolic-associated liver diseases. Discussions included updated recommendations and emerging therapeutic approaches for managing these conditions. Latest Clinical Trial Readouts The conference concluded with significant data from recent clinical trials, summarizing key findings and their implications for current and future diabetes management practices. Dr. Anya Yastrobov, Dr. Rupa Mehta, Dr. Roy Taylor, and Dr. David Nathan provided an in-depth review of what newly diagnosed Type 2 diabetes patient management should be focused on in 2024.

ADA’s 85th Scientific Sessions Preview

Where will ADA be in 2025? ADA 2025 is in Chicago, IL. From June 20 to 23, 2025, attendees will gather at McCormick Place. How many people attend the ADA Scientific Sessions? ADA 2025 will again bring together thousands of healthcare professionals, researchers, and industry leaders dedicated to advancing diabetes care. The 85th Scientific Sessions are expected to generate an attendance of over 15,000 attendees. Meet Orange Biomed at ADA 2025 in Chicago! The ADA’s leading diabetes conference in 2025 promises to be another exciting and informative event, highlighting advancements and innovations that will empower healthcare providers and patients. Join Orange Biomed next year in Chicago, where we will present the latest advancements in A1C tests at home following our anticipated FDA clearance in 2025. For more information about OBM rapid A1c, reach out to us.

We Were There –
Diabetes Technology Meeting

We proudly attended the Diabetes Technology Meeting 2024 from October 15-17 in Burlingame, CA. During the event, we showcased our OBM rapid A1c system at the Startup Showcase and shared insights on advancing equitable diabetes care. It was a fantastic opportunity to connect, learn, and present innovative solutions for better diagnostics.